Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK

This article was originally published in The Pink Sheet Daily

Executive Summary

Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.

You may also be interested in...



GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva

GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.

Tokai Raises $23 Million In Series D Financing

The start up's focus is on a highly competitive indication, refractory prostate cancer, but its ability to raise money could be tied to the novelty of its lead compound

Tokai Raises $23 Million In Series D Financing

The start up's focus is on a highly competitive indication, refractory prostate cancer, but its ability to raise money could be tied to the novelty of its lead compound

Related Content

Topics

UsernamePublicRestriction

Register

PS068662

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel